Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 350 participants.
Also called NCT07227246
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 350 participants
- Registry
-
NCT07227246
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, Germany, Japan, Spain, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07227246. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-06 (actual); primary completion 2029-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
- Acronym
- FASTEST Part 2
- Condition
- Intracerebral Hemorrhage
- Intervention (Biological)
- Recombinant Factor VIIa
- Intervention (Biological)
- Biological/Vaccine: Placebo
- Lead sponsor
- Joseph Broderick, MD
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator
- Japan Agency for Medical Research and Development
- Collaborator
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07227246- Content hash
30d9be44ef3ab76437c7d79d4ada510e41427035c24fd16e5d65bf60e159e334